Belumosudil: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Belumosudil. Educational only — not medical advice.
Labeled uses
REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Source: FDA labeling via NIH DailyMed (set 102e4ef4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.